|2nd November 2020||Floyd F. Petersen||500||Open or private sale||$19.84||$9,919.95|
|1st October 2020||Floyd F. Petersen||500||Open or private sale||$18.89||$9,445.80|
|1st September 2020||Floyd F. Petersen||500||Open or private sale||$19.90||$9,948.05|
|14th August 2020||William J Peters||5,512||Open or private sale||$20.36||$112,223.22|
|14th August 2020||David Maris||1,000||Open or private purchase||$20.26||$20,260.00|
|11th August 2020||Richard K Prins||6,000||Open or private sale||$20.33||$121,976.40|
|3rd August 2020||Floyd F. Petersen||500||Open or private sale||$20.62||$10,307.75|
|21st July 2020||Yakob Liawatidewi||5,978||Open or private sale||$21.22||$126,837.02|
|21st July 2020||Yakob Liawatidewi||5,978||Exercise of derivative||$11.33||$67,730.74|
|20th July 2020||Yakob Liawatidewi||4,186||Open or private sale||$21.03||$88,046.65|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.